Regeneron plunges on US FDA delay of wet AMD drug
This article was originally published in Scrip
Executive Summary
Regeneron's hopes were dashed on 16 August of having its experimental neovascular age-related macular degeneration (wet AMD) drug Eylea (aflibercept) available for patients before the end of the summer after the US FDA delayed by three months its decision on whether to approve the medicine's biologic license application (BLA).